留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

Lox-1—心血管疾病防治的新靶标

李倩,  芮耀诚

downloadPDF
文章导航 > 药学实践与服务  > 2014 >  32(5): 321-323
李倩, 芮耀诚. Lox-1—心血管疾病防治的新靶标[J]. 药学实践与服务, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
引用本文: 李倩, 芮耀诚. Lox-1—心血管疾病防治的新靶标[J]. 药学实践与服务, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
shu
LI Qian, RUI Yaocheng. Lox-1, a new target in cardiovascular disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
Citation: LI Qian, RUI Yaocheng. Lox-1, a new target in cardiovascular disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
shu

Lox-1—心血管疾病防治的新靶标

doi: 10.3969/j.issn.1006-0111.2014.05.001

  • 第二军医大学药学院药理学教研室, 上海 200433

Lox-1, a new target in cardiovascular disease

  • Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 摘要: 目的 Lox-1(血凝素样氧化低密度脂蛋白受体1),是ox-LDL的主要受体之一,在血管内皮功能障碍、泡沫细胞形成及动脉粥样硬化斑块的稳定性中具有重要作用。 方法 为了探讨Lox-1在心血管疾病中的作用,笔者对有关Lox-1在心血管疾病中的研究进展进行回顾性分析。 结果 Lox-1作为ox-LDL新型清道夫受体,在心血管疾病的发生发展中具有重要的作用。 结论 Lox-1可能为防治心血管疾病的药物研究提供新的思路。
    Abstract: Objective Lox-1 (lectin-like oxidized low-density lipoprotein receptor-1) was one of the main receptor of ox-LDL, which took an important role in vascular endothelial dysfunction, the formation of foam cells, and the stability of atherosclerotic plaques. To investigate the role of Lox-1 in cardiovascular diseases. Methods The literatures of Lox-1 in cardiovascular diseases retrospectively were reviewed. Results As a new ox-LDL scavenger receptor, Lox-1 played an important role in cardiovascular diseases. Conclusion Lox-1 might provide new ideas for cardiovascular diseases.
  • [1] Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein[J]. Nature, 1997, 386:73-77.
    [2] Mehta JL, Li DY. Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells[J]. Biochem Biophys Res Commun, 1998, 248:511-514.
    [3] Chen M, Kakutani M, Naruko T,et al. Activation-dependent surface expression of lox-1 in human platelets[J]. Biochem Biophys Res Commun, 2001, 282(1):153-158.
    [4] Chen XP, Du GH. Lectin like oxidized low-density lipoprotein receptor-1:protein, ligands, expression and pathophysiological significance[J]. Chin Med J, 2007, 120(5):421-626.
    [5] Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity[J]. Curr Opin Immunol, 2002, 14:123-128.
    [6] Nickel T, Schmauss D, Hanssen H, et al. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation[J]. Atherosclerosis, 2009, 205(2):442-450.
    [7] Chen XP, Zhang TT, Du GH. Lectin-like oxidized low-density Lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis[J]. Cardiovas Drug Rev, 2007, 25(2):146-161.
    [8] Mehta JL, Sanada N, Hu CP, et al. Deletion of olr1 reduces atherogenesis in ldlr knockout mice fed high cholesterol diet[J]. Circ Res, 2007, 100:1634-1642.
    [9] Sona M, Tanu G, Jawahar L,et al. Oxidized ldl, lox-1 and atherosclerosis[J]. Cardiovasc Drugs Ther, 2011, 25(5):419-429.
    [10] Hirokazu M, Noriaki K, Kazutaka H, et al. Interleukin 18 stimulates release of soluble lectin-like oxidized ldl receptor-1 (slox-1)[J]. Atherosclerosis,2009, 202:176-182.
    [11] Magomed Khaidakov, Sona Mitra, Xianwei Wang, et al. Oxidized ldl receptor 1 (olr1) as a possible link between obesity,dyslipidemia and cancer[J]. Plos One, 2011, 6(5):e20277.
    [12] Xu SW, Ogura S, Chen JW, et al. Lox-1 in atherosclerosis:biological functions and pharmacological modifiers[J]. Cell Mol Life Sci, 2013, 70(6):2859-2872.
    [13] Matarazzo S, Quitadamo MC, Mango R, et al. Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption[J]. Mol Pharmacol, 2012, 82(2):246-254.
    [14] Mehta JL, Chen J, Yu F, et al. Aspirin inhibits ox-LDL mediated Lox-1 expression and metalloproteinase-1 in human coronary endothelial cells[J]. Cardiovasc Res, 2004, 64(2):243-249.
    [15] Chen JW, Zhou SB, Tan ZM. Aspirin and pravastatin reduce lectin-like oxidized low density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells[J]. Chin Med J, 2010, 123(12):1553-1556.
    [16] Pang T, Wang J, Benicky J, et al. Minocycline ameliorates lps-induced inflammation in human monocytes by novel mechanisms including Lox-1,nur77 and litaf inhibition[J]. Biochim Biophys Acta, 2012, 1820(4):503-510.
    [17] Li L, Renier G. The oral anti-diabetic agent, gliclazide, inhibits oxidized ldl-mediated lox-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells[J]. Atherosclerosis, 2009, 204(1):40-46.
    [18] Xu S, Liu Z, Huang Y, et al. Tanshinone Ⅱ-A inhibits oxidized LDL induced Lox-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation[J]. Transl Res, 2012, 160(2):114-124.
    [19] Kang BY, Khan JA, Ryu S, et al. Curcumin reduces angiotensin Ⅱ-mediated cardiomyocyte growth via Lox-1 inhibition[J]. J Cardiovasc Pharmacol, 2010, 55(2):176-183.
    [20] Guan S, Wang B, Li W, et al. Effects of berberine on expression of Lox-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL[J]. Am J Chin Med, 2010, 38(6):1161-1169.
    [21] Lee WJ,Ou HC, Chou MM, et al. Ellagic acid inhibits oxidized LDL-mediated Lox-1 expression, ROS generation, and inflammation in human endothelial cells[J]. J Vasc Surg, 2010, 52(5):1290-1300.
    [22] Ou HC, Song TY, Yeh YC, et al. EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting Lox-1-mediated signaling[J]. J Appl Physiol, 2010, 108(6):1745-1756.
    [23] Chang HC, Chen TG, Tai YT, et al. Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells[J]. J Cereb Blood Flow Metab, 2011, 31(3):842-854.
    [24] Taye A, Saad AH, Kumar AH, et al. Effect of apocynin on NADPH oxidase-mediated oxidative stress-Lox-1-eNOS pathway in human endothelial cells exposed to high glucose[J]. Eur J Pharmacol, 2010, 627(1-3):42-48.
    [25] Lee MJ, Lee HS, Park SD, et al. Leonurus sibiricus herb extract suppresses oxidative stress and ameliorates hypercholesterolemia in C57BL/6 mice and TNF-alpha induced expression of adhesion molecules and lectin-like oxidized LDL receptor-1 in human umbilical vein endothelial cells[J]. Biosci Biotechnol Biochem, 2010, 74(2):279-284.
    [26] Shibata Y, Kume N, Arai H, et al. Mulberry leaf aqueous fractions inhibit TNF-alpha-induced nuclear factor kappaB (NF-kappaB) activation and lectin-like oxidized LDL receptor-1(Lox-1) expression in vascular endothelial cells[J]. Atherosclerosis, 2007, 193(1):20-27.
  • [1] 张修平, 田家盛, 王道鑫, 李佳鑫, 王品, 缪朝玉.  MT-1207对血糖、血脂和动脉粥样硬化的作用 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202306011
    [2] 王智聪, 谢彬, 袁星, 徐希科, 柳润辉.  基于网络药理学探讨麝香保心丸治疗动脉粥样硬化作用机制 . 药学实践与服务, 2023, 41(5): 296-301. doi: 10.12206/j.issn.2097-2024.202112001
    [3] 王道鑫, 张添光, 缪朝玉.  血管内皮细胞线粒体氧化应激与动脉粥样硬化 . 药学实践与服务, 2023, 41(6): 329-334, 392. doi: 10.12206/j.issn.2097-2024.202205116
    [4] 谢彬, 袁星, 徐希科, 柳润辉.  中药复方抗动脉粥样硬化作用机制的研究进展 . 药学实践与服务, 2021, 39(4): 295-298, 304. doi: 10.12206/j.issn.1006-0111.202103001
    [5] 王品, 齐齐, 郑斯莉, 徐浩展, 缪朝玉.  动脉粥样硬化高脂饲料对小鼠糖脂水平的作用研究 . 药学实践与服务, 2021, 39(2): 121-125. doi: 10.12206/j.issn.1006-0111.202012002
    [6] 林张军, 李倩, 章越凡, 芮耀诚.  巨噬源性泡沫细胞中p62蛋白上调作用和机制的研究 . 药学实践与服务, 2019, 37(5): 400-405,426. doi: 10.3969/j.issn.1006-0111.2019.05.004
    [7] 钱俞君, 秦春霞, 孙莉莉, 丁华敏, 李铁军.  建立以HIF-1α为靶标的高通量筛选防治动脉粥样硬化先导化合物的细胞模型 . 药学实践与服务, 2019, 37(1): 27-31. doi: 10.3969/j.issn.1006-0111.2019.01.007
    [8] 干润, 霍炎, 黄金路, 杨全军, 郭澄.  孤儿核受体NR4A1与动脉粥样硬化的研究进展 . 药学实践与服务, 2016, 34(4): 292-296. doi: 10.3969/j.issn.1006-0111.2016.04.002
    [9] 毛峻琴, 侯中海, 陈大贵, 张文.  贻贝多糖MA对实验性动脉粥样硬化兔的作用 . 药学实践与服务, 2014, 32(1): 27-30. doi: 10.3969/j.issn.1006-0111.2014.01.007
    [10] 刘佃花, 张恩晖, 刘冲, 范博士, 蔡国君.  烟碱致动脉粥样硬化的N胆碱受体信号通路 . 药学实践与服务, 2014, 32(2): 81-84. doi: 10.3969/j.issn.1006-0111.2014.02.001
    [11] 李帆, 芮耀诚.  IRAK-4在白介素-1受体/Toll样受体(IL-1R/TLRs)介导的炎症信号通路中的关键作用 . 药学实践与服务, 2011, 29(1): 1-3,14.
    [12] 蒋国军, 张黎, 李铁军, 邱彦, 楼宜嘉.  洛伐他汀对氧化修饰低密度脂蛋白刺激U937细胞缺氧诱导因子-1α表达的影响 . 药学实践与服务, 2009, 27(3): 170-173.
    [13] 韩保民, 陈筠, 陈光表.  固体药品密度的测定 . 药学实践与服务, 2008, (6): 455-456.
    [14] 任天舒, 李林鹏, 姜远英.  高胆固醇血症大鼠自由基代谢紊乱及阿托伐他汀的干预作用 . 药学实践与服务, 2007, (3): 143-144,149.
    [15] 陈巧玲, 蔡宝祥.  他汀类药物防治动脉粥样硬化作用研究进展 . 药学实践与服务, 2006, (6): 321-324.
    [16] 张旭静, 孔建龙, 黄久仪, 王桂清.  中药抗动脉粥样硬化作用研究进展 . 药学实践与服务, 2004, (6): 321-323.
    [17] 王晶, 潘勇华, 王旭明, 刘建飞.  光敏剂及其临床应用进展 . 药学实践与服务, 2002, (2): 67-70.
    [18] 刘悦, 唐全红.  辅酶Q10对LDL氧化的抑制作用——论辅酶Q在动脉粥样化形成中的保护机制 . 药学实践与服务, 2001, (2): 119-119.
    [19] 曹国英, 徐樟永, 董晓敏, 赵燕, 宫曙光, 张尊祥, 戴新民, 李爱平, 程吟梅.  金匮肾气丸及其加味对中老年人甲襞微循环及载脂蛋白的影响 . 药学实践与服务, 1991, (2): 58-60.
    [20] 苟奎斌, 龙焜.  甲硝呋胍和甲氰咪胍对健康人体血浆脂蛋白的影响 . 药学实践与服务, 1987, (2): 16-16.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1949
  • HTML全文浏览量:  281
  • PDF下载量:  573
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-02-27
  • 修回日期:  2013-10-23

Lox-1—心血管疾病防治的新靶标

doi: 10.3969/j.issn.1006-0111.2014.05.001
  • 第二军医大学药学院药理学教研室, 上海 200433
  • 收稿日期: 2013-02-27
  • 修回日期: 2013-10-23

摘要: 目的 Lox-1(血凝素样氧化低密度脂蛋白受体1),是ox-LDL的主要受体之一,在血管内皮功能障碍、泡沫细胞形成及动脉粥样硬化斑块的稳定性中具有重要作用。 方法 为了探讨Lox-1在心血管疾病中的作用,笔者对有关Lox-1在心血管疾病中的研究进展进行回顾性分析。 结果 Lox-1作为ox-LDL新型清道夫受体,在心血管疾病的发生发展中具有重要的作用。 结论 Lox-1可能为防治心血管疾病的药物研究提供新的思路。

English Abstract

李倩, 芮耀诚. Lox-1—心血管疾病防治的新靶标[J]. 药学实践与服务, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
引用本文: 李倩, 芮耀诚. Lox-1—心血管疾病防治的新靶标[J]. 药学实践与服务, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
shu
LI Qian, RUI Yaocheng. Lox-1, a new target in cardiovascular disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
Citation: LI Qian, RUI Yaocheng. Lox-1, a new target in cardiovascular disease[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(5): 321-323. doi: 10.3969/j.issn.1006-0111.2014.05.001
shu

    全文HTML

参考文献 (26)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计